Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Figures & data

Figure 1 Mucus layer, epithelium, and lamina propria of the small and large intestine.

Figure 2 Orally delivery or injection of NPs to the inflamed intestinal epithelium with impaired epithelial cells and permeable blood vessel.

Table 1 US Food And Drug Administration Approved Multi-Responsive Oral Drug Delivery Systems For IBD Treatment

Drug	Active Ingredient	NP Formulation	Mechanism Of Release
CODES^Citation130,Citation131	Mesalamine (mesalazine, or aminosalicylate [5-ASA])	Polysaccharide/pH-sensitive polymer	Bacteria-degradation & pH-dependent
DELZICOL*		Methacrylic acid copolymer type B & polyethylene glycol & hydroxypropyl methylcellulose (HPMC)	pH-dependent & time-delayed; delayed release
LIALDA^Citation132,Citation133*		Multi-Matrix system with Hydrophobic/hydrophilic coating	pH-dependent & time-delayed; prolonged-release
MEZAVANT^Citation134		Multi-Matrix system with Lipophilic/hydrophilic coating	pH-dependent & time-delayed; prolonged release
Entocort EC^Citation135	Budesonide	Gelatin capsules with enteric-coated granules	pH-dependent & time-depended;
Uceris^Citation136		Multi-Matrix system with Hydrophobic/hydrophilic coating	pH-dependent & time-delayed; extended-release
TARGIT^Citation137		pH-sensitive coatings onto injection-moulded starch	Bacteria-degradation & pH-dependent

Note: *Source: the professional version of Merck manual (https://www.merckmanuals.com).

Figure 3 Structures of plant-derived nanoparticles (PDNPs), exosome, and synthetic nanoparticles (artificial liposomes). (A) Major forms of PDNPs, (B) mammalian exosome, and (C) major forms of the artificial liposomes. Reprinted with permission from The Royal Society of Chemistry. Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6(9):1312–1321.⁴⁰

Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M. Studies on lactulose formulations for colon-specific drug delivery. Int J Pharm. 2002;249(1–2):33–43. doi:10.1016/S0378-5173(02)00429-512433432

 PubMedGoogle Scholar

Abinusawa A, Tenjarla S. Release of 5-Aminosalicylic Acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;32(5):477–484. doi:10.1007/s12325-015-0206-425951927

 PubMedGoogle Scholar

Yu A, Baker JR, Fioritto AF, et al. Measurement of in vivo gastrointestinal release and dissolution of three locally acting mesalamine formulations in regions of the human gastrointestinal tract. Mol Pharm. 2017;14(2):345–358. doi:10.1021/acs.molpharmaceut.6b0064128009518

 PubMedGoogle Scholar

Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX((R)) mesalamine. Clin Pharmacol. 2012;4:41–50. doi:10.2147/CPAA.S2655622888278

 PubMedGoogle Scholar

Goyanes A, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484(1–2):103–108. doi:10.1016/j.ijpharm.2015.02.05125721685

 PubMed Web of Science ®Google Scholar

Nicholls A, Harris-Collazo R, Huang M, Hardiman Y, Jones R, Moro L. Bioavailability profile of Uceris MMX extended-release tablets compared with entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41(2):386–394. doi:10.1177/030006051347658823569029

 PubMed Web of Science ®Google Scholar

Sinha SR, Nguyen LP, Inayathullah M, et al. A thermo-sensitive delivery platform for topical administration of inflammatory bowel disease therapies. Gastroenterology. 2015;149(1):52–55 e52. doi:10.1053/j.gastro.2015.04.00225863215

 PubMed Web of Science ®Google Scholar

Watts P, Smith A. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv. 2005;2(1):159–167. doi:10.1517/17425247.2.1.15916296742

 PubMedGoogle Scholar

Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6(9):1312–1321. doi:10.1039/C7TB03207B30034807

 PubMed Web of Science ®Google Scholar